Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrasound-Guided Multimodal Thermal Therapy Plus Tislelizumab for First-Recurrent HCC
ChiCTR2500106696Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: 1-year relapse-free survival rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500106696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106696.